NCT00850044已完成1 期
A Double-Blind, Randomized, Placebo-Controlled, Nonfasting Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Doses of ABT-450 With and Without Ritonavir
AbbVie1 个研究点 分布在 1 个国家目标入组 87 人开始时间: 2009年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 87
- 试验地点
- 1
- 主要终点
- Pharmacokinetics (blood draws, pre- and post-dose)
研究概览
简要总结
The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •overall healthy subjects
- •non-childbearing potential females included
排除标准
- •history of significant sensitivity to any drug
- •positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab
- •history of gastrointestinal issues or procedures
- •history of seizures, diabetes or cancer (except basal cell carcinoma)
- •clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder
- •use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration
- •donation or loss of 550 mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration
- •abnormal screening laboratory results that are considered clinically significant by the investigator
- •current enrollment in another clinical study
- •previous enrollment in this study
- •recent (6-month) history of drug/alcohol abuse that could preclude adherence to the protocol
- •pregnant or breastfeeding female
- •requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis
研究组 & 干预措施
1
Active Comparator
ABT-450
干预措施: ABT-450 (Drug)
2
Placebo Comparator
Placebo for ABT-450
干预措施: placebo for ABT-450 (Drug)
3
Active Comparator
ABT-450/ritonavir
干预措施: ABT-450 (Drug)
3
Active Comparator
ABT-450/ritonavir
干预措施: ritonavir (Drug)
4
Placebo Comparator
Placebo for ABT-450/placebo for ritonavir
干预措施: placebo for ABT-450 (Drug)
4
Placebo Comparator
Placebo for ABT-450/placebo for ritonavir
干预措施: Placebo for ritonavir (Drug)
结局指标
主要结局
Pharmacokinetics (blood draws, pre- and post-dose)
时间窗: 4 days
Safety and Tolerability (ECGs, AEs, vitals, physical exams, routine labs)
时间窗: 10 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy SubjectsThrombosisNCT03197779Bristol-Myers Squibb691
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese ParticipantsHealthy VolunteersNCT05813717Bristol-Myers Squibb25
已完成
2 期
Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral NeuropathyPainful Diabetic Peripheral NeuropathyNCT05123196Tanabe Pharma Corporation156
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy AdultsHealthy Adult SubjectsNCT04629131Zhuhai Trinomab Pharmaceutical Co., Ltd.32
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy AdultsHealthy VolunteersNCT05842798Zhuhai Trinomab Pharmaceutical Co., Ltd.28